Table 3.
Results of major pembrolizumab trials based on CPS score.
| Name of trial | Line of Rx | CPS prevalence | OS (months) | PFS (months) | ORR (%) | References | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥1 | ≥10 | 0 | ≥1 | ≥10 | 0 | ≥1 | ≥10 | 0 | ≥1 | ≥10 | |||
| KEYNOTE-059 | ≥3 | 57% | NA | 4.9 | 5.8 | NA | NA | NA | NA | 6 | 16 | NA | (36) |
| KEYNOTE-061 | 2 | 66% | 18% | 4.8 | 9.1 | 10.4 | NA | 1.5 | NA | 2 | 16 | 9 | (25) |
| KEYNOTE-062 (Pembro) |
1 | All | 36%* | NA | 10.6 | 17.4 | NA | 2.0 | 2.9 | NA | 15 | 25 | (28) |
| KEYNOTE-062 (Pembro + chemo) |
1 | All | 36%* | NA | 12.5 | 12.3 | NA | 6.9 | 5.7 | NA | 49 | 53 | (28) |
| KEYNOTE-181 (EC) |
2 | NR | 35% | 7.1+ | 9.3 | 2.1+ | 2.6 | 13+ | 22 | (15) | |||
| KEYNOTE-180 (EC) |
≥3 | NR | 48% | NR | 6.3 | NR | 2.0 | NR | 14 | (39) | |||
*
this is the prevalence of CPS ≥ 10 within this trial, which is a biomarker selected population of CPS ≥ 1.
+
this trial did not differentiate between CPS 0, and CPS ≥ 1, and the survival/response rates reported here is for the entire trial population (regardless of CPS score).
Pembro, pembrolizumab; chemo, chemotherapy; EC, esophageal carcinoma; NA, not applicable; NR, not reported.